Autolus Therapeutics (AUTL)
NASDAQ:AUTL
Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$1.60
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.60
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.18 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.57M
Market Cap
$497.71M
Enterprise Value$446.72M
Total Cash (Recent Filing)$229.43M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Jul 30, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume1,839,907
30 Day Avg. Volume1,569,988
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue4.82
Enterprise Value/Gross Profit-43.12
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$8.08Price Target Upside405.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$129.66M
Bulls Say, Bears Say
Bulls Say
Rapid Commercial Revenue GrowthSustained, large YoY revenue growth from AUCATZYL demonstrates clear commercial traction and product-market fit for the ALL franchise. Reiterated full‑year guidance ($120–$135M) and expanding treatment centers support durable mid‑term revenue visibility and scaling potential.
Positive Gross Profit And Unit Economics RoadmapAchieving a positive gross profit marks a structural shift: higher volumes and manufacturing improvements show meaningful operating leverage. Management's peak margin targets imply that per‑unit economics can support profitability at scale, making future company profit achievable if overheads and production scale align.
Strong Clinical And Real‑world Efficacy Supporting AdoptionRobust real‑world safety and efficacy reinforce clinical differentiation and reimbursement arguments, aiding provider adoption and payer coverage. Multiple upcoming trial and registry readouts create durable optionality to expand indications and grow addressable markets beyond the initial ALL launch.
Bears Say
High Cash Burn And Limited RunwayPersistent, large operating cash outflows require ongoing financing or material margin improvement to avoid dilution. Even with cost actions, current liquidity only extends to Q4‑2027; fundraising or milestone execution will be needed during commercialization, reducing financial flexibility and increasing dilution risk.
Company‑level Losses And Negative MarginsDespite revenue progress, company‑level operating and net margins remain deeply negative, reflecting a cost base far above current revenue. Continued high SG&A for commercialization plus R&D needs mean company profitability depends on sustained revenue growth and tight cost control over multiple years.
Execution Risk In Manufacturing Scale‑up And Europe AccessScaling manufacturing and completing technology transfers are material operational risks that could delay volume growth and margin targets. Separately, unresolved European market access and MFN negotiations create structural uncertainty for ex‑US revenue timing and the company's ability to achieve projected global scale.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.18 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $497.71M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 58 days.
How were Autolus Therapeutics’s earnings last quarter?
Autolus Therapeutics released its earnings results on May 14, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.017.
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.23.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,155,800 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Autolus Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went down -7.018%.
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.08 (405.00% Upside)
$8.08 (405.00% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.14%
12-Months-Change
Fundamentals
Return on Equity
-128.53%
Trailing 12-Months
Asset Growth
-29.38%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected strong commercial momentum and operational progress: quarterly revenue surged (~191% YoY), the company achieved its first positive gross margin quarter, and production efficiency initiatives target lower per-unit costs and $15M annualized savings in 2027. Real-world data and multiple near- and mid-term clinical readouts underpin a promising pipeline and support expansion into new indications and geographies. Offsetting these positives are continued high net losses, significant cash drawdown (cash runway into Q4 2027), a sizable rise in SG&A to support commercialization, and execution risks related to manufacturing scale-up and European market access. Overall, while financial and execution risks remain, the balance of substantial commercial progress, margin improvement, and clear pipeline milestones leads to a constructive outlook.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.08
▲(405.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
40.45% Other Institutional Investors
58.52% Public Companies and Individual Investors